Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Myeloid Malignancy clinical trials
Every US clinical trial registered for Myeloid Malignancy — phase mix, recruiting status, and the sponsors running them, straight from the NIH ClinicalTrials.gov registry.
8 US clinical trials · 7 currently recruiting
The research picture
Myeloid Malignancy has 8 registered US clinical trials, 7 of them open to new participants right now — about 88% of the total.
- 7
- recruiting participants now
- 88%
- of trials open to enrollment
- 0
- in Phase 3–4 (later-stage)
- 2
- top sponsor: University of Rochester
Counts reflect the public ClinicalTrials.gov registry as last mirrored by PlainTrial. Status and phase are reported by each study's sponsor. This is reference information, not medical advice.
Active & Recent Trials
Pre-myeloid Cancer and Bone Marrow Failure Clinic Study
Mayo Clinic
NCT02958462
A Telehealth Advance Care Planning Intervention
University of Rochester
NCT05875805
Considering alloHCT: Opportunities for Patient Reflection During Decision-Making Via Digital Stories
University of Rochester
NCT07263074
HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML
Masonic Cancer Center, University of Minnesota
NCT06594445
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
Henry Ford Health System
NCT03850418
Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant
Benjamin Tomlinson
NCT06129734
Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies
University of Alabama at Birmingham
NCT07044544
Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms
Jacqueline Garcia, MD
NCT05455294
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 1 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Reading the Myeloid Malignancy Trial Landscape
ClinicalTrials.gov lists 8 US studies indexed under Myeloid Malignancy, and 7 of those are currently open to recruitment — roughly 88% of the total volume on the registry. That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.
The phase distribution for Myeloid Malignancy shows 0 late-stage studies (Phase 3 and Phase 4 combined) alongside 5 earlier-phase entries (Phase 1 through Phase 2). Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.
Top sponsor activity for Myeloid Malignancy is led by University of Rochester with 2 indexed trials, alongside 6 other organizations in the top contributor list. The list on this page surfaces up to 8 of the most relevant recent and active entries, ordered with recruiting studies first so practical options are visible. All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation — eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.
Frequently Asked Questions
How many clinical trials are there for Myeloid Malignancy?
PlainTrial tracks 8 US clinical trials for Myeloid Malignancy, of which 7 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Myeloid Malignancy?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology — how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.